

Balaxi Pharmaceuticals Limited

Date: 09.04.2026

Place: Hyderabad

To
Mr. Amit Shinde,
Chief Manager - Surveillance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir,

Subject: Clarification on Movement in Price

This is with reference to **NSE Letter No: NSE/CM/Surveillance/16689 dated 08th April, 2026** with respect to significant movement in price of our Equity Shares listed with NSE, in the recent past; which required us to submit response on the same.

In this regard, we would like to inform you that there is no material information/announcement with the Company which may have a bearing on the price / volume behaviour in the scrip of the Company. **The movement in price of our scrip is purely market driven.**

We would like to further submit that the Company has been complying with all the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015 within the stipulated period from time to time.

The Company will adhere to all the compliance requirements and will keep the Exchange informed of all the information in the future as well.

This is for your information and records.

Regards,

**On Behalf of
Balaxi Pharmaceuticals Limited**

**Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345**

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in